Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

Rhea-AI Summary

Alumis (Nasdaq: ALMS) announced that Phase 3 ONWARD 1 and 2 results for envudeucitinib will be presented as a late‑breaking oral presentation at the 2026 AAD Annual Meeting on March 28, 2026, at 11:12 am MDT.

A Phase 2 STRIDE biomarker analysis will appear as an e‑poster (poster 73714). Alumis will host an investor webcast on March 29, 2026 at 5:00 pm MDT to review the ONWARD data; presentations and a replay will be posted on the company website on March 28–29, 2026.

News Market Reaction – ALMS

-3.01%

1 alert

-3.01% News Effect

-$94M Valuation Impact

$3.04B Market Cap

0.1x Rel. Volume

On the day this news was published, ALMS declined 3.01%, reflecting a moderate negative market reaction. This price movement removed approximately $94M from the company's valuation, bringing the market cap to $3.04B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

PASI 75 response: 74% sPGA 0/1: 59% PASI 90 response: ≈65% +5 more

8 metrics

PASI 75 response 74% Phase 3 ONWARD psoriasis program Week 16 (Jan 2026 topline release)

sPGA 0/1 59% Phase 3 ONWARD psoriasis program Week 16 (Jan 2026 topline release)

PASI 90 response ≈65% Phase 3 ONWARD psoriasis program Week 24 (Jan 2026 topline release)

PASI 100 response >40% Phase 3 ONWARD psoriasis program Week 24 (Jan 2026 topline release)

ONWARD enrollment over 1,700 patients Two parallel Phase 3 psoriasis trials (ONWARD1 and ONWARD2)

LUMUS SLE enrollment 408 patients Global LUMUS Phase 2b trial in systemic lupus erythematosus

LUMUS treatment duration 48 weeks Phase 2b SLE trial treatment period

AAD 2026 dates March 27–31, 2026 American Academy of Dermatology Annual Meeting in Denver

Market Reality Check

Price: $25.09 Vol: Volume 1,366,995 is rough...

normal vol

$25.09 Last Close

Volume Volume 1,366,995 is roughly in line with 20-day average 1,345,321 (relative volume 1.02x). normal

Technical Shares at $26.22 are trading above the $10.31 200-day moving average, reflecting a strong pre-event uptrend.

Peers on Argus

ALMS is nearly flat (+0.04%) while close biotech peers show a mixed tape (e.g., ...

ALMS is nearly flat (+0.04%) while close biotech peers show a mixed tape (e.g., ATXS +0.8%, CRVS -1.72%, ERAS -1.11%). Current setup appears stock-specific rather than a coordinated sector move.

Previous Clinical trial Reports

5 past events · Latest: Jan 06 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 06	Phase 3 topline data	Positive	+95.3%	Positive Phase 3 psoriasis results for envudeucitinib with strong PASI and sPGA outcomes.
Jul 24	Phase 2b SLE enrollment	Positive	+0.5%	Completion of enrollment in 408-patient LUMUS Phase 2b SLE trial for ESK-001.
May 29	ONWARD enrollment complete	Positive	-0.8%	Completion of enrollment in two Phase 3 ONWARD psoriasis trials with over 1,700 patients.
Mar 08	Phase 2 OLE data	Positive	-0.6%	Positive 52-week Phase 2 STRIDE OLE psoriasis data presented at 2025 AAD.
Feb 28	AAD 2025 presentation plan	Positive	-0.4%	Announcement of late-breaking and e-poster psoriasis data plus accelerated ONWARD Phase 3 readout.

Pattern Detected

Clinical updates have often been positive, but immediate price reactions have been mixed; only the January 2026 Phase 3 topline created a very large upside move.

Recent Company History

Over the past year, Alumis has steadily advanced its TYK2 program. The company completed enrollment of the pivotal Phase 3 ONWARD psoriasis program with over 1,700 patients, and reported highly positive Phase 3 topline data in Jan 2026 with strong PASI and sPGA responses, driving a large one-day gain. Earlier, it completed enrollment of the 408-patient LUMUS Phase 2b SLE trial and presented 52-week Phase 2 OLE psoriasis data at AAD 2025. Today’s AAD late-breaker notice fits this pattern of using major dermatology meetings to showcase maturing clinical data.

Historical Comparison

+18.8% avg move · In the past 12 months, ALMS has issued 5 clinical-trial updates with an average move of 18.81%. Toda...

clinical trial

+18.8%

Average Historical Move clinical trial

In the past 12 months, ALMS has issued 5 clinical-trial updates with an average move of 18.81%. Today’s pre-event move of 0.04% sits well below that historical reaction.

Clinical news shows a clear progression: Phase 2 STRIDE data at AAD 2025, completion of Phase 3 ONWARD enrollment, highly positive Phase 3 topline psoriasis results, and ongoing expansion into SLE via the 408-patient LUMUS Phase 2b trial.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-07-03

Alumis has an active Form S-3 shelf filed on 2025-07-03, currently noted as not yet effective, with at least one 424B5 takedown on 2026-01-08. This indicates the company has used shelf capacity for prior capital raising, though no aggregate dollar capacity is specified here.

Market Pulse Summary

This announcement highlights that detailed 24-week Phase 3 ONWARD1/2 psoriasis data for envudeucitin...

Analysis

This announcement highlights that detailed 24-week Phase 3 ONWARD1/2 psoriasis data for envudeucitinib and new Phase 2 STRIDE biomarker analyses will be showcased as a late-breaking presentation at AAD 2026. Historically, Alumis has used AAD to advance visibility of its TYK2 program, following strong Phase 2 and Phase 3 results and enrollment milestones. Investors may watch for deeper efficacy, safety and biomarker details relative to prior topline data and how these might support planned regulatory steps.

Key Terms

phase 3, phase 2, tyrosine kinase 2 (TYK2), randomized, +4 more

8 terms

phase 3 medical

"24-week results from the randomized, double-blind, active comparator- and placebo-controlled, Phase 3 ONWARD 1 and 2 studies"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

phase 2 medical

"Phase 2 STRIDE e-poster presentation to describe disease biomarker activity of envudeucitinib"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

tyrosine kinase 2 (TYK2) medical

"envudeucitinib, a next-generation oral tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe plaque psoriasis"

Tyrosine kinase 2 (TYK2) is a human enzyme that acts like a switch inside immune cells, helping control signals that turn inflammation and immune responses on or off. Investors watch TYK2 because drugs that block or tweak this switch can treat autoimmune diseases and certain cancers, so clinical trial results, regulatory approval, patents and potential sales can materially change the value of drug developers targeting TYK2.

randomized medical

"24-week results from the randomized, double-blind, active comparator- and placebo-controlled, Phase 3 ONWARD 1 and 2 studies"

Randomized means participants or units in a study are assigned to different groups by chance rather than by choice, like flipping a coin to decide who gets a new treatment and who gets a comparison. For investors, randomized designs matter because they reduce bias and make results more trustworthy, so outcomes from randomized studies carry more weight when assessing regulatory approval, commercial prospects, and the risk that trial results will change a company’s valuation.

double-blind medical

"24-week results from the randomized, double-blind, active comparator- and placebo-controlled, Phase 3 ONWARD 1 and 2 studies"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"24-week results from the randomized, double-blind, active comparator- and placebo-controlled, Phase 3 ONWARD 1 and 2 studies"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

biomarkers medical

"disease biomarker activity of envudeucitinib – – Alumis to host investor webcast"

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

transcriptomic medical

"at Both a Proteomic and Transcriptomic Level: A Subgroup Analysis of Tape Strip Biomarkers"

Transcriptomic describes anything related to the transcriptome — the complete set of RNA messages a cell or tissue makes at a given time, which shows which genes are actively being used. Think of it like a snapshot of which recipes are being cooked in a kitchen; for investors, transcriptomic data matters because it helps identify drug targets, predict treatment response, and validate whether a therapy is affecting biology as intended, all of which can change a company’s development prospects and valuation.

AI-generated analysis. Not financial advice.

– Phase 3 data presentation highlighting results from the ONWARD1 and ONWARD2 clinical trials of envudeucitinib –

– Phase 2 STRIDE e-poster presentation to describe disease biomarker activity of envudeucitinib –

– Alumis to host investor webcast on Sunday, March 29, 2026, at 5:00 pm MDT / 7:00 pm EDT –

SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that results from its Phase 3 ONWARD program evaluating envudeucitinib, a next-generation oral tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe plaque psoriasis, have been accepted for a late-breaking oral presentation, and that a new biomarker analysis from the Phase 2 STRIDE trial of envudeucitinib has been accepted as an e-poster at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place March 27–31, 2026, in Denver, Colorado.

Details regarding the presentations are as follows: 

Late-Breaking Oral Presentation
Title: Envudeucitinib (ESK-001) in moderate-to-severe plaque psoriasis: 24-week results from the randomized, double-blind, active comparator- and placebo-controlled, Phase 3 ONWARD 1 and 2 studies
Location: Bellco Theatre 3
Date and Time: March 28, 2026, at 11:12 am MDT

E-Poster Presentations
Title: Envudeucitinib Attenuates Inflammatory Biomarkers in Plaque Psoriasis at Both a Proteomic and Transcriptomic Level: A Subgroup Analysis of Tape Strip Biomarkers from the STRIDE Phase 2 Clinical Trial
Poster number: 73714

The presentations will be made available under the Publications section of the Alumis website on March 28, 2026 in accordance with the AAD embargo policy.

Investor Conference Call and Webcast Details
Alumis will also host a webcast for the investment community on Sunday, March 29, 2026, at 5:00 pm MDT (7:00 pm EDT) to review the Phase 3 ONWARD data being presented at AAD. The live webcast can be accessed via this link or on the Events tab on the Investors section of the Company’s website. A replay of the webcast will be made available on the Company’s website following the call.

About Envudeucitinib 
Envudeucitinib is a next‑generation, highly selective, oral allosteric inhibitor of tyrosine kinase 2 (TYK2) designed to correct immune dysregulation across a range of diseases driven by proinflammatory mediators, including IL-23, IL-17, and Type I interferon. Clinical data indicate its selective targeting delivered sustained, maximal 24-hour inhibition in patients with psoriasis while minimizing off-target binding and effects. Alumis is currently evaluating the long-term efficacy and safety of envudeucitinib in the Phase 3 ONWARD3 clinical program for moderate-to-severe plaque psoriasis. Envudeucitinib is also being evaluated in LUMUS, a potentially pivotal Phase 2b clinical trial in patients with systemic lupus erythematosus, with topline data expected in the third quarter of 2026.

About Alumis
Alumis is a late-stage biopharma company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, the pipeline includes lonigutamab, a subcutaneously delivered anti–insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach. For more information, visit www.alumis.com or follow us on LinkedIn or X.

Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Alumis’ future plans and prospects including development and commercialization of its pipeline, Alumis’ expectations with respect to the timing of availability of topline data from its clinical trials, any expectations regarding the safety, efficacy or tolerability of envudeucitinib or A-005, the potential of envudeucitinib to treat moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and the potential of A-005 to treat neurodegenerative diseases. Any forward-looking statements in this press release are based on Alumis’ current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results, levels of activity, safety, efficacy, performance or events and circumstances could differ materially from those expressed or implied in Alumis’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to Alumis’ ability to advance envudeucitinib and A-005 and to obtain regulatory approval of and ultimately commercialize Alumis’ clinical candidates, the timing and results of preclinical and clinical trials, Alumis’ ability to fund development activities and achieve development goals, Alumis’ ability to protect its intellectual property and other risks and uncertainties described in Alumis’ filings with the Securities and Exchange Commission (SEC), including any future reports Alumis may file with the SEC from time to time. Alumis explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Alumis Contact Information
Teri Dahlman
Red House Communications
teri@redhousecomms.com

FAQ

What will Alumis (ALMS) present about envudeucitinib at AAD 2026 on March 28, 2026?

Alumis will present 24‑week Phase 3 ONWARD 1 and 2 results in a late‑breaking oral session. According to the company, the presentation covers randomized, double‑blind, active‑comparator and placebo‑controlled 24‑week data for moderate‑to‑severe plaque psoriasis.

When and where is Alumis (ALMS) hosting the investor webcast to review ONWARD Phase 3 data?

The investor webcast is scheduled for March 29, 2026 at 5:00 pm MDT (7:00 pm EDT). According to the company, the live webcast link is on the Events tab of the Investors section and a replay will be posted afterward.

What is the STRIDE Phase 2 e‑poster from Alumis (ALMS) at AAD 2026 about?

The STRIDE e‑poster (poster 73714) reports envudeucitinib effects on proteomic and transcriptomic tape‑strip biomarkers. According to the company, it describes subgroup biomarker activity showing attenuation of inflammatory markers in plaque psoriasis samples.

Where can investors access the ONWARD presentations and replay for Alumis (ALMS)?

Presentations will be available under the Publications section of the company website on March 28, 2026 and the webcast replay posted after March 29. According to the company, materials follow AAD embargo timing and will be hosted online.

What is the exact timing of Alumis's late‑breaking oral presentation at AAD for ALMS?

The late‑breaking oral presentation is on March 28, 2026 at 11:12 am MDT in Bellco Theatre 3. According to the company, this session will present 24‑week results from the randomized ONWARD 1 and 2 trials.